Transcriptomics

Dataset Information

0

RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature


ABSTRACT: Improving outcomes in multiple myeloma will not only involve development of new therapies, but better use of existing treatments. We performed RNA sequencing (RNA-Seq) on samples from newly diagnosed patients enrolled into the phase II PADIMAC study. Using an empirical Bayes approach and synthetic annealing, we developed and trained a seven-gene signature to predict treatment outcome. We tested the signature on independent cohorts treated with bortezomib- and lenalidomide-based therapies. The signature was capable of distinguishing which patients would respond better to which regimen. In the CoMMpass dataset, patients who were treated correctly according to the signature had a better progression-free and overall survival than those who were not. Indeed, the outcome for these correctly treated patients was non-inferior to those treated with combined bortezomib, lenalidomide, and dexamethasone (VRD). PADIMAC: Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (autologous stem cell transplant)

ORGANISM(S): Homo sapiens

PROVIDER: GSE116324 | GEO | 2018/06/28

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2015-01-20 | E-GEOD-57317 | biostudies-arrayexpress
2015-01-20 | GSE57317 | GEO
2011-09-30 | E-GEOD-31421 | biostudies-arrayexpress
2011-08-20 | GSE8991 | GEO
2011-08-19 | E-GEOD-8991 | biostudies-arrayexpress
2011-09-30 | E-GEOD-31451 | biostudies-arrayexpress
2011-10-01 | GSE31451 | GEO
2011-10-01 | GSE31421 | GEO
2016-09-28 | GSE87403 | GEO
2021-01-27 | GSE161195 | GEO